SCHEMBL6715699

SCHEMBL6715699

O=C(O)c1ccccc1N1CCc2ccccc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
ALDH1A1 P00352 6/20 0.51
HPGD P15428 1/20 0.50
NOTUM Q6P988 2/20 0.49
ALOX15 P16050 1/20 0.48
MEN1 O00255 2/20 0.47
MAPT P10636 2/20 0.47
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
TSHR P16473 2/20 0.47
TP53 P04637 1/20 0.46
PKM P14618 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10625670 0.90 SMN1; SMN2 (0.54) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL28341426 0.87 NPC1 (0.48) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL156641 0.81 MEN1 (0.57) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL5347900 0.81 ALDH1A1 (0.50) L3MBTL1ALDH1A1ALOX15MEN1KMT2A
SCHEMBL28173573 0.79 NOTUM (0.43) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL13890895 0.77 NPC1 (0.48) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL22226225 0.77 HPGD (0.54) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL29784320 0.77 ALDH1A1 (0.53) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL22442390 0.77 ALDH1A1 (0.53) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL30689042 0.77 ALDH1A1 (0.48) NPC1RAB9AALDH1A1HPGDNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040039208-A1 Process for making n-aryl-anthranilic acids and their derivatives CHEN MICHAEL HUAI GU (US) 2004-02-26 US disclosed
CN-1458921-A Process for making N-aryl-anthranilic acid and their derivatives WARNER LAMBERT CO (US) 2003-11-26 CN disclosed
EP-1313694-A1 PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES WARNER-LAMBERT COMPANY (US) 2003-05-28 EP disclosed
WO-2002018319-A1 PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES WARNER-LAMBERT COMPANY LLC (US) 2002-03-07 WO disclosed
US-4764616-A ANALGESIC, ANTIPHYCHOTIC HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-08-16 US disclosed
US-4761412-A Benzopyrrolobenzodiazepines and quinobenzodiazepines useful for the treatment of psychoses HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-08-02 US disclosed
US-4723007-A ANALGESICS, ANTIPSYCHOTIC AGENTS; INTERMEDIATES FOR PROCESSING HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-02-02 US disclosed
US-4723003-A ANTIPSYCHOTIC AGENTS, ANALGESICS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-02-02 US disclosed
US-4663453-A Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1987-05-05 US disclosed
EP-0129692-A2 Dibenzodiazepin derivatives, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1985-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039208-A1 Process for making n-aryl-anthranilic acids and their derivatives AADAC, AHR, AADAT NPC1 2888/4885RAB9A 2898/4885L3MBTL1 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.